

## Correction: New Perspectives of Curcumin in Cancer Prevention

In this review article (Cancer Prev Res 2013;6:387–400), which was published in the May 2013 issue of *Cancer Prevention Research* (1), the text within Table 1, a list of completed clinical trials using curcumin, contained a typographical error pertaining to curcumin dosage. Specifically, Table 1 referred to a phase II clinical trial conducted by Cruz-Correa and colleagues, with the following description: "Patients: 5, Oral curcumin 480 g + quercetin 20 mg t.i.d. for 180 days." The text incorrectly reported curcumin dosage in grams rather than milligrams. With this correction, the affected portion of Table 1 now accurately reads, "Patients: 5, Oral curcumin 480 mg + quercetin 20 mg t.i.d. for 180 days."

The online version of the article has been corrected and therefore no longer matches the print version. The authors regret this error.

### Reference

1. Park W, Amin ARMR, Chen ZG, Shin DM. New perspectives of curcumin in cancer prevention. *Cancer Prev Res* 2013;6:387–400.

Published OnlineFirst May 18, 2017.

doi: 10.1158/1940-6207.CAPR-17-0126

©2017 American Association for Cancer Research.

